| scholarly article | Q13442814 |
| P50 | author | Guillermo Martín-Gutiérrez | Q61122722 |
| Jesus Blazquez | Q68273789 | ||
| José Manuel Rodríguez Martínez | Q54449621 | ||
| Jerónimo Rodríguez-Beltrán | Q59677616 | ||
| Alvaro Pascual | Q60594097 | ||
| P2093 | author name string | Javier Aznar | |
| Coloma Costas | |||
| P2860 | cites work | Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli | Q67969436 |
| Conditions affecting the results of susceptibility testing for the quinolone compounds | Q67999655 | ||
| Urine pH variation dynamics in healthy individuals and stone formers | Q68678693 | ||
| Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin | Q69996489 | ||
| Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose | Q79353868 | ||
| Physicochemical properties of antibacterial compounds: implications for drug discovery | Q80662325 | ||
| Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection | Q82694773 | ||
| Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine | Q83354580 | ||
| Emerging mechanisms of fluoroquinolone resistance | Q24644842 | ||
| Influence of diet on acid-base balance | Q28142510 | ||
| Physiological approach to assessment of acid-base disturbances | Q28249362 | ||
| International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases | Q28304595 | ||
| Potential renal acid load of foods and its influence on urine pH. | Q34059092 | ||
| Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series | Q35115778 | ||
| Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. | Q36048167 | ||
| Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments | Q36105056 | ||
| Mechanisms of drug resistance: quinolone resistance | Q36225422 | ||
| The mode of action of quinolones: The paradox in activity of low and high concentrations and activity in the anaerobic environment | Q36670132 | ||
| Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study | Q37405774 | ||
| Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? | Q38031214 | ||
| Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. | Q39470224 | ||
| Human bladder urine oxygen content: implications for urinary tract diseases | Q40657667 | ||
| Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae | Q41511968 | ||
| Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. | Q42201141 | ||
| Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment | Q42229251 | ||
| Urinary tract infections in solid organ transplantation | Q42272264 | ||
| Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns | Q43167548 | ||
| MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids | Q43527362 | ||
| A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria | Q43837240 | ||
| Predicting the exposure and antibacterial activity of fluoroquinolones based on physicochemical properties | Q43905787 | ||
| Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients | Q44197906 | ||
| Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? | Q44259675 | ||
| Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions | Q44701302 | ||
| Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms | Q44778107 | ||
| Association of urinary pH with body weight in nephrolithiasis | Q44845992 | ||
| Increased acid excretion in kidney stone formers with essential hypertension | Q46420003 | ||
| Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS. | Q46421940 | ||
| Mechanism of quinolone mutagenicity in bacteria | Q50187884 | ||
| High-protein diets and renal status in rats. | Q50871500 | ||
| Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. | Q51500519 | ||
| Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. | Q54185007 | ||
| Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. | Q54444750 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| quinolones | Q426549 | ||
| P304 | page(s) | 4252-4258 | |
| P577 | publication date | 2016-06-20 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli | |
| P478 | volume | 60 |
| Q33601794 | Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections |
| Q40368674 | Plasmidic qnr Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. |
| Q48179364 | Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. |
Search more.